Szepetowski Pierre
Mediterranean Institute of Neurobiology (INMED), Inserm U901, parc scientifique de Luminy, BP 13, 13273 Marseille cedex 09, France.
Presse Med. 2018 Mar;47(3):218-226. doi: 10.1016/j.lpm.2017.10.020. Epub 2017 Dec 23.
Numerous epilepsy genes have been identified in the last years, mostly in the (rare) monogenic forms and thanks to the increased availability and the decreased cost of next-generation sequencing approaches. Besides the somehow expected group of epilepsy genes encoding various ion channel subunits (e.g. sodium or potassium channel subunits, or GABA receptors, or glutamate-gated NMDA receptors), more diversity has emerged recently, with novel epilepsy genes encoding proteins playing a wide range of physiological roles at the cellular and molecular levels, such as synaptic proteins, members of the mTOR pathway, or proteins involved in chromatin remodeling. The overall picture is somehow complicated: one given epilepsy gene can be associated with more than one epileptic phenotype, and with variable degrees of severity, from the benign to the severe forms (e.g. epileptic encephalopathies), and with various comorbid conditions such as migraine or autism spectrum of disorders. Conversely, one given epileptic syndrome may be associated with different genes, some of which have obvious links with each other (e.g. encoding different subunits of the same receptor) while other ones have no clear relationships. Also genomic copy number variations have been detected, some of which, albeit rare, may confer high risk to epilepsy. Whereas translation from gene identification to targeted medicine still remains challenging, progress in epilepsy genetics is currently revolutionizing genetic-based diagnosis and genetic counseling. Epilepsy gene identification also represents a key entry point to start in deciphering the underlying pathophysiological mechanisms via the design and the study of the most pertinent cellular and animal models - which may in turn provide proofs-of-principle for future applications in human epilepsies.
在过去几年中,已经鉴定出许多癫痫基因,这主要得益于新一代测序技术的普及和成本降低,这些基因大多以(罕见的)单基因形式存在。除了编码各种离子通道亚基(如钠或钾通道亚基、GABA受体或谷氨酸门控的NMDA受体)的癫痫基因外,最近出现了更多样化的情况,新的癫痫基因编码的蛋白质在细胞和分子水平上发挥着广泛的生理作用,如突触蛋白、mTOR通路成员或参与染色质重塑的蛋白质。总体情况有些复杂:一个特定的癫痫基因可能与不止一种癫痫表型相关,且严重程度各不相同,从良性到严重形式(如癫痫性脑病),还伴有各种合并症,如偏头痛或自闭症谱系障碍。相反,一种特定的癫痫综合征可能与不同的基因相关,其中一些基因彼此有明显联系(如编码同一受体的不同亚基),而另一些则没有明确关系。此外,还检测到基因组拷贝数变异,其中一些虽然罕见,但可能会使患癫痫的风险很高。虽然从基因鉴定到靶向药物的转化仍然具有挑战性,但癫痫遗传学的进展目前正在彻底改变基于基因的诊断和遗传咨询。癫痫基因鉴定也是通过设计和研究最相关的细胞和动物模型来开始解读潜在病理生理机制的关键切入点,这反过来可能为未来在人类癫痫中的应用提供原理证明。